Allergan to buy Pa.-based Vicept

August 3, 2011

Allergan will pay as much as $275 million to acquire Vicept Therapeutics, the Orange County (Calif.) Business Journal reports.

Irvine, Calif. - Allergan, based here, will pay as much as $275 million to acquire Vicept Therapeutics, the Orange County (Calif.) Business Journal reports.

Allergan will pay $75 million for the company, based in Malvern, Pa., and up to $200 million in future milestone payments. Vicept’s V-101, a cream for treating redness associated with rosacea, is in mid-stage clinical trials. Vicept has two other products in the early stages of development.

An Allergan spokesman said the acquisition enhances the company’s dermatology research and development pipeline.